More on Questcor (QCOR -6.4%): Aetna's (AET +0.3%) latest bulletin shows no change from its...

|By:, SA News Editor

More on Questcor (QCOR -6.4%): Aetna's (AET +0.3%) latest bulletin shows no change from its position first taken in September on Acthar. The insurer is still limiting reimbursement of the drug only for the treatment of infantile spasms. AET asserts that the drug's other approved uses are medically unnecessary or unproven.